| Identification | Back Directory | [Name]
3-(4-oxo-3(4H)-quinazolinyl)-N-[4-(1-piperidinylsulfonyl)phenyl]propanamide | [CAS]
701225-07-2 | [Synonyms]
IRF1-IN-1
3(4H)-Quinazolinepropanamide, 4-oxo-N-[4-(1-piperidinylsulfonyl)phenyl]-
3-(4-oxo-3(4H)-quinazolinyl)-N-[4-(1-piperidinylsulfonyl)phenyl]propanamide
3-(4-oxoquinazolin-3(4H)-yl)-N-[4-(piperidin-1-ylsulfonyl)phenyl]propanamide | [Molecular Formula]
C22H24N4O4S | [MOL File]
701225-07-2.mol | [Molecular Weight]
440.52 |
| Hazard Information | Back Directory | [Uses]
IRF1-IN-1 (Compound I-2) is an IRF1 inhibitor. IRF1-IN-1 decreases the recruitment of IRF1 to the promoter of CASP1. IRF1-IN-1 inhibits cell death signaling pathway (i.e., cleavage of Caspase 1, GSDMD, IL-1 and PARP1). IRF1-IN-1 has a protective effect on ionizing radiation-induced inflammatory skin injury[1]. | [in vivo]
IRF1-IN-1 pretreatment (100?μg/d, s.c., one every other day before irradiation) has a potential protective effect in 35 Gy radiation-induced inflammatory skin injury mice[1].
| Animal Model: | Radiogenic skin injury mice (intraperitoneal injection of pentobarbital sodium (1%, 30 mg/kg), 35 Gy at the dose rate of 1000 cGy/min by a 6-MeV electron beam)[1] | | Dosage: | 100 μg/d | | Administration: | Subcutaneous injection (s.c.), one every other day before irradiation, pretreatment | | Result: | Showed a significant reduction in acute skin inflammatory manifestations, such as erythema and exudation and accelerated the healing process.
Showed protective effects on the function and structural integrity of radiation-induced lesions to the claws.
|
| [IC 50]
PARP-1; IL-1; Caspase-1 | [References]
[1] Geng, et al. Chaperone- and PTM-mediated activation of IRF1 tames radiation-induced cell death and the inflammatory response. Cell Mol Immunol. 2024 Aug;21(8):856-872. DOI:10.1038/s41423-024-01185-3 |
|
| Company Name: |
Specs
|
| Tel: |
+31 15 251 8111 |
| Website: |
www.specs.net |
|